<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01366482</url>
  </required_header>
  <id_info>
    <org_study_id>P-4941</org_study_id>
    <nct_id>NCT01366482</nct_id>
  </id_info>
  <brief_title>Atherectomy Followed by a Drug Coated Balloon to Treat Peripheral Arterial Disease</brief_title>
  <acronym>DEFINITIVE AR</acronym>
  <official_title>Directional AthErectomy Followed by a PaclItaxel-Coated BallooN to InhibiT RestenosIs and Maintain Vessel PatEncy: A Pilot Study of Anti-Restenosis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MEDRAD, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DEFINITIVE AR study is a prospective, multi-center, randomized pilot study evaluating the
      use of either the TurboHawk™ or SilverHawk® plaque excision systems followed by treatment
      with the Cotavance™ drug-eluting balloon catheter versus the Cotavance balloon catheter alone
      in patients with peripheral arterial disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Percent Stenosis</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Peripheral Arterial Disease,</condition>
  <condition>Claudication</condition>
  <arm_group>
    <arm_group_label>Drug-eluting balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Plaque excision followed by a drug-eluting balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Randomized Arm (severely calcified lesions)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with severe calcification will be assigned to a non-randomized arm and treated with plaque excision followed by a drug-eluting balloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cotavance Drug-Eluting Balloon</intervention_name>
    <description>Treatment with a Paclitaxel-coated angioplasty balloon (without preceding plaque excision)</description>
    <arm_group_label>Drug-eluting balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TurboHawk/SilverHawk Device followed by a Cotavance Drug-Eluting Balloon</intervention_name>
    <description>Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon</description>
    <arm_group_label>Plaque excision followed by a drug-eluting balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TurboHawk/SilverHawk Device followed by a Cotavance Drug-Eluting Balloon (N=25)</intervention_name>
    <description>Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon</description>
    <arm_group_label>Non-Randomized Arm (severely calcified lesions)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rutherford Clinical Category 2-4

          -  At least 18 years of age

          -  Is able and willing to provide written informed consent prior to study specific
             procedures

        Exclusion Criteria:

          -  Has a life expectancy of less than 24 months

          -  Is pregnant, of childbearing potential not taking adequate contraceptive measures, or
             nursing

          -  Has one or more of the contraindications listed in the SilverHawk/ TurboHawk or
             Cotavance IFUs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Thomas Zeller</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herz-Zentrum Bad Krozingen Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Professor Gunnar Tepe</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Rosenheim Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2011</study_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral arterial disease,</keyword>
  <keyword>claudication,</keyword>
  <keyword>atherectomy,</keyword>
  <keyword>plaque excision,</keyword>
  <keyword>drug-coated balloon</keyword>
  <keyword>drug-eluting balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

